CCL2 and metabolic dysfunction-associated steatotic liver disease: In order to establish the relevance of targeting CCR2/CCL2 and FGF21 in humans, we analyzed serum CCL2 and FGF-21 levels in 85 patients with biopsy-confirmed NAFLD.